Bone disease and bisphosphonates in multiple myeloma

Nowotwory

Volumn 51, Issue 2, 2001, Pages 151-156

  Kraj, M ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Bisphosphonates; Clodronate; Multiple myeloma; Osteolytic lesions; Pamidronate

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANEMIA; BONE ATROPHY; BONE PAIN; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCALCEMIA; KIDNEY FUNCTION; MULTIPLE MYELOMA; REVIEW; TREATMENT INDICATION;

EID: 0034911839     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Modulation of osteoclast differentation and function by the new members of the tumor necrosis factor receptor and ligand families
2. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of multiple myeloma
3. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma
4. Abnormal bone remodeling in patients with myelomatosis and normal biochemical indices of bone resorption
5. Quantitative histology of myeloma-induced bone changes
6. Excessive bone resorption in human plasmocytomas: Direct induction by tumour cells themselves
7. The role of the osteoclast differentiation factor TRANCE in myeloma-associated bone destruction
8. Ocena wystȩpowania zmian kostnych w przebiegu szpiczaka plazmocytowego, chłoniaków nieziarniczych i ziarnicy złośliwej
9. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation bone resorption, and kinase activation in vitro
10. Nitrogen -containing bisphosphonates inhibit the mevalonate pathway and prevent post translational prenylation of GTP-binding proteins, including Ras
11. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
12. Characteristics of clodronate -induced apoptosis in osteoclasts and macrophages
13. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
14. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
15. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway
16. Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system
17. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
18. Anti-myeloma activity of pamidronate in vivo
19. Effect of daily etidronate on the osteolysis of multiple myeloma
20. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
21. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
22. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene) -1,1-bisphosphonate (A.P.D.)
23. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial
24. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: A multicenter study
25. Long-term clodronate treatment reduces skeletal morbidity but does not prolong survival of multiple myeloma patients with osteolysis
26. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy
27. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma
28. Randomised, placebo controlled multicentre trial of clodronate in multiple myeloma
29. Use of pamidronate for multiple myeloma osteolytic lesions
30. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
31. A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma
32. Treatment of bone metastases from breast cancer and myeloma with pamidronate
33. The effect of very long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma
34. Reparacja szpiczakowych uszkodzeń osteolitycznych krȩgów w wyniku leczenia napromienianiem i pamidronianem
35. Early progression adapted use of bisphosphonates in myeloma
36. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcaemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages
37. Effective treatment of malignant hypercalcaemia with single intravenous infusion of clodronate
38. A randomised double blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
39. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound
40. A dose-finding study of zolendronate in hypercalcemic cancer patients
41. Current use of bisphosphonates in oncology